QRICH1 and neoplasm: In the GSE78220 dataset with 28 melanoma patients, the expression level of QRICH1 before PD-1 treatment was significantly lower in the complete response group compared to the partial response and progressive disease groups (Fig. 8G), supporting the immunomodulatory role of QRICHI in the tumor immunity.